Y-mAbs Therapeutics, Inc. provided earnings guidance for the year 2024. The company anticipated DANYELZA net product revenues of between $95 million and $100 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
14.06 USD | -18.27% | -15.28% | +104.84% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+104.84% | 755M | |
+3.38% | 106B | |
+7.02% | 23.47B | |
-14.96% | 21.9B | |
-7.05% | 18.77B | |
-38.55% | 17.85B | |
-10.00% | 16.78B | |
+5.76% | 14.41B | |
+34.93% | 12.86B | |
+319.59% | 8.78B |
- Stock Market
- Equities
- YMAB Stock
- News Y-mAbs Therapeutics, Inc.
- Y-mAbs Therapeutics, Inc. Provides Earnings Guidance for the Year 2024